Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colon cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GIcancers. The most prevalent digestivecancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma (...) relative with BEor esophageal adenocarcinoma [EAC]). – For pancreatic cancerscreening, endoscopic ultra- sound may be used in selected high-risk patients such as those with a strong family history and/or genetic suscep- tibility. ABBREVIATIONS BE Barrett’sesophagus CT computed tomography EAC esophageal adenocarcinoma ESGE European Societyof Gastrointestinal Endoscopy EUS endoscopic ultrasound FIT fecal immunochemical testing FOBT fecal occult blood test GERD gastroesophageal reflux diseaseGI
or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).mp. 4. 2 or 3 5. 1 and 4 6. ((colonography or colonoscopy (...) or screening).ti,ab. or "early detection of cancer"/ 20. (neoplasms/ or breast neoplasms/ or colorectalneoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breast neoplasms/ or colonicneoplasms/ or rectal neoplasms/) and (di or pc).fs. 21. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 22. 20 or 21 23
Have inflammatory boweldisease Have hereditary syndromes that increase the risk of colorectalcancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectalcancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectalcancerscreening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowelcancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer
Colorectalcancerscreening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis Evaluate effectiveness, harms and burdens of faecal blood testing, sigmoidoscopy and colonoscopy screening for colorectalcancer over 15 years.We performed an update of a Cochrane systematic review, and performed network meta-analysis comparing randomised trials evaluating colorectalcancerscreening with guaiac faecal occult blood test (gFOBT) (annual, biennial), faecal (...) immunochemical test (FIT) (annual, biennial), sigmoidoscopy (once-only) or colonoscopy (once-only) in a healthy population, aged 50-79 years. We conducted subgroup analysis on sex. Follow-up >5 years was required for analysis of colorectalcancer incidence and mortality.12 randomised trials proved eligible. Compared with no-screening, we found high certainty evidence for sigmoidoscopy screening slightly reducing colorectalcancer incidence (relative risk (RR) 0.76; 95% confidence interval (CI 0.70 to 0.83
Colorectalcancerscreening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. To estimate benefits and harms of different colorectalcancerscreening strategies, stratified by (baseline) 15-year colorectalcancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection (...) of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectalcancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk
with a personal or family history of colorectalcancer or adenomatous polyps, persons with inflammatory boweldisease, and those with symptoms that may be attributable to colorectal. Background Recently, the American Cancer Society (ACS) released their updated 2018 ColorectalCancer (CRC) Screening Guidelines. These guidelines added the qualified recommendation* that screening for average risk patients start at 45 years of age regardless of race. Screening all adults aged 50 years and older, which (...) fruits and vegetables, fiber, and calcium). Awareness Given the data that colorectalcancer is increasing in younger individuals we must be more vigilant for signs and symptoms that could indicate a problem. I want to know if you develop blood in your stools, anemia, abdominal pain, or changes in bowel habits. However, it is also important to realize that early coloncancers and precancerous polyps do not commonly cause symptoms. 5 References American Academy of Family Physicians Statement: https
Towards risk-stratified colorectalcancerscreening. Adding risk factors to the fecal immunochemical test: Evidence, evolution and expectations With increasing incidence and mortality, colorectalcancer (CRC) is a growing health problem worldwide. An effective way to address CRC is by screening for fecal (occult) blood by the fecal immunochemical test (FIT). However, there is room for improvement since precursor lesions and CRC bleed intermittent and can therefore be missed by the FIT (false
Comparison of Universal Versus Age-Restricted Screening of ColorectalTumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study. Guidelines recommend screening all patients with newly diagnosed colorectalcancer (CRC) for Lynch syndrome (LS). However, the efficiency of universal LS screening in elderly populations has not been well studied.To compare the performance of age-restricted and universal LS screening using reflex mismatch repair (MMR) immunohistochemistry (...) (IHC) of CRC tumors.Retrospective cohort study.A large, diverse, community-based health care system.3891 persons with newly diagnosed CRC who had LS screening between 2011 and 2016.Diagnostic yield of different LS screening strategies.Sixty-three LS cases (diagnostic yield, 1.62%) were identified by universal screening, with only 5 (7.9%) detected after age 70 years and 1 (1.6%) detected after age 80 years. When all patients with CRC who had universal screening were used as the denominator, 58 LS
Participation and Ease of Use in ColorectalCancerScreening: A Comparison of 2 Fecal Immunochemical Tests The impact of fecal immunochemical test (FIT)-based colorectalcancer (CRC) screening on disease incidence and mortality is affected by participation, which might be influenced by ease of use of the FIT. We compared the participation rates and ease of use of 2 different FITs in a CRC screening program.There were two study designs within the Dutch CRC screening program. In a paired cohort (...) but marginally considered easier to use than OC-Sensor, the number of analyzable tests and the participation rates in organized CRC screening are not affected when either of the FITs is implemented as a primary screening test.
Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for ColorectalCancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(23):2564-2575. . Centers for Disease Control and Prevention. National Health Interview Survey. Available at: . Published March 1, 2014. Accessed June 21, 2018. .National Cancer Institute. SEER Cancer Statistics Fact sheets: Colon and Rectum Cancer. Available at: .Published September, 2014. Accessed June 21, 2018 (...) will continue to improve, and blood tests for CRC are in development. Research and one blood test, Epi pro Colon, was approved by the FDA in 2016. However, it is not currently recommended by the USPSTF. As this area of research develops, it is important that physicians remain aware of all the currently available USPTSF-approved screening modalities. “One size fits all” may not be the most effective cancerscreening approach for all patients. Studies have shown that colonoscopy may be avoided by large
of CRC or advanced adenoma warrants more intense screening for CRC. Well-designed prospective studies are needed in order to make de?nitive evidence-based recommendations about the age to commence screening and appropriate interval between screening tests. Keywords: Adenoma; Cancer; Colonoscopy; Colorectal; FOBT; Neoplasms; Polyp; Screening. Executive Summary Colorectalcancer (CRC) is the second leading cause of cancer deaths in Canada and the United States. A positive family history (FH) signi (...) with papillary thyroid cancer that is the cribriform-morular variant, or hepatoblastoma Individuals with a diagnosis of CRC and>10 colorectal adenomas Individuals with a personal history of20 adenomas Individuals with multiple gastrointestinal hamartomatous polyps or serrated polyposis syndrome Individuals from a family with a known hereditary syndrome associated with CRC with or without a known mutation Individuals with a desmoid tumor, multifocal or bilateral CHRPE CHRPE, congenital hypertrophy of retinal
) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectalcancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping (...) Dental radiograph as an opportunistic screening tool for a colorectalcancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectalcancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP
Population health interventions to improve colorectalcancerscreening by fecal immunochemical tests: A systematic review Despite clear evidence that colorectalcancer (CRC) screening reduces mortality, screening, including fecal immunochemical tests (FIT), is underutilized. We conducted a systematic review to determine the evidence of efficacy of interventions to improve FIT completion that could be scaled and utilized in population health management. We systematically searched publication (...) databases for studies evaluating provider- or system-level interventions to improve CRC screening by FIT between 1 January 1996 and 13 December 2017 without language restrictions. Twenty articles describing 25 studies were included, 23 were randomized controlled trials with 1 quasi-experimental and 1 observational study. Ten studies discussed mailed FIT outreach, 4 pre-FIT patient reminders, 3 tailored patient messages, 2 post-FIT reminders, 2 paired FIT with influenza vaccinations, 2 provider alerts
Evaluation of Interventions Intended to Increase ColorectalCancerScreening Rates in the United States: A Systematic Review and Meta-analysis Colorectalcancerscreening (CRC) is recommended by all major US medical organizations but remains underused.To identify interventions associated with increasing CRC screening rates and their effect sizes.PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and ClinicalTrials.gov were searched from January 1, 1996 (...) , to August 31, 2017. Key search terms included colorectalcancer and screening.Randomized clinical trials of US-based interventions in clinical settings designed to improve CRC screening test completion in average-risk adults.At least 2 investigators independently extracted data and appraised each study's risk of bias. Where sufficient data were available, random-effects meta-analysis was used to obtain either a pooled risk ratio (RR) or risk difference (RD) for screening completion for each type
Recent advances in colorectalcancerscreening 30276360 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Recent advances in colorectalcancerscreening. 139-147 10.1016/j.cdtm.2018.08.004 Li Dan D Department of Gastroenterology, Kaiser Permanente Medical Center, Santa Clara, CA 95051, USA. Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. eng Editorial 2018 09 17 China Chronic Dis Transl Med 101679934 2095 (...) -882X Colonoscopy ColorectalcancerScreening 2018 06 26 2018 10 3 6 0 2018 10 3 6 0 2018 10 3 6 1 epublish 30276360 10.1016/j.cdtm.2018.08.004 S2095-882X(18)30060-4 PMC6160607 Lancet. 2013 Apr 6;381(9873):1185-93 23414648 Am J Surg Pathol. 2004 Nov;28(11):1452-9 15489648 Gastroenterology. 2016 Nov;151(5):870-878.e3 27443823 CA Cancer J Clin. 2017 May 6;67(3):177-193 28248415 Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7 26226577 Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330
percentage points; 95% CI, 0.1%-6.8%) and any colorectalcancerscreening (18.3% vs 14.5%; difference, 3.8 percentage points; 95% CI, 0.6%-7.0%). We observed large variation across health centers in effectiveness (FIT completion differences range, -7.4 percentage points to 17.6 percentage points) and implementation (proportion who were mailed a FIT range, 6.5% to 68.2%). The number needed to mail to achieve a completed FIT was 4.8 overall, and 4.0 in clinics that mailed a FIT reminder.An EHR-embedded (...) Effectiveness of a Mailed ColorectalCancerScreening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Approximately 24 million US individuals receive care at federally qualified health centers, which historically have low rates of colorectalcancerscreening. The US Preventive Services Task Force recommends routine colorectalcancerscreening for individuals aged 50 to 75 years.To determine the effectiveness of an electronic health record (EHR
for Disease Control and Prevention (CDC's) Screen for Life materials. Some participants also will be asked to read a personal narrative about coloncancerscreening . This study will determine whether participant's perceptions about 2015 16. Colon Capsule to Screen for ColorectalNeoplasia in Subjects with a Family History of ColorectalCancer . BACKGROUND AND AIMS: Colon capsule endoscopy (CCE) has been recognized as an alternative for colorectalcancer (CRC) screening in average risk subjects (...) administration is a key factor in the tolerability and efficacy of colon preparation in colorectalcancerscreening ]. 236-42 10.1016/j.gastrohep.2012.01.012 The quality and tolerability of antegrade (...) gut lavage bowel preparation are key elements in the success of population-based colorectalcancerscreening . To evaluate cleansing quality and tolerability according to the timing of polyethylene glycol administration in persons undergoing colorectalcancerscreening . Participants in colorectalcancer
Incidence of faecal occult blood test interval cancers in population-based colorectalcancerscreening: a systematic review and meta-analysis Faecal immunochemical tests (FITs) are replacing guaiac faecal occult blood tests (gFOBTs) for colorectalcancer (CRC) screening. Incidence of interval colorectalcancer (iCRC) following a negative stool test result is not yet known. We aimed to compare incidence of iCRC following a negative FIT or gFOBT.We searched Ovid Medline, Embase, Cochrane Library (...) , Science Citation Index, PubMed and Google Scholar from inception to 12 December 2017 for citations related to CRC screening based on stool tests. We included studies on FIT or gFOBT iCRC in average-risk screening populations. Main outcome was pooled incidence rate of iCRCs per 100 000 person-years (p-y). Pooled incidence rates were obtained by fitting random-effect Poisson regression models.We identified 7 426 records and included 29 studies. Meta-analyses comprised data of 6 987 825 subjects